Nanobiotix S.A. (NANO.PA)
EUR 3.48
(1.93%)
EUR 3.48
(1.93%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -26.77 Million EUR | 39.82% |
| 2022 | -50.49 Million EUR | -1.39% |
| 2021 | -49.8 Million EUR | -28.05% |
| 2020 | -38.89 Million EUR | 20.94% |
| 2019 | -49.19 Million EUR | -63.61% |
| 2018 | -30.06 Million EUR | -19.0% |
| 2017 | -25.26 Million EUR | -15.61% |
| 2016 | -21.85 Million EUR | -27.49% |
| 2015 | -17.14 Million EUR | -78.19% |
| 2014 | -9.61 Million EUR | -17.61% |
| 2013 | -8.17 Million EUR | -58.74% |
| 2012 | -5.15 Million EUR | 1.42% |
| 2011 | -5.22 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -23.65 Million EUR | 0.0% |
| 2023 FY | -30.38 Million EUR | 39.82% |
| 2023 Q4 | -1.4 Million EUR | 0.0% |
| 2023 Q2 | -28.66 Million EUR | 0.0% |
| 2022 Q4 | -24.24 Million EUR | 0.0% |
| 2022 FY | -50.49 Million EUR | -1.39% |
| 2022 Q2 | -26.24 Million EUR | 0.0% |
| 2021 Q4 | -24.13 Million EUR | 0.0% |
| 2021 FY | -49.8 Million EUR | -28.05% |
| 2021 Q2 | -25.67 Million EUR | 0.0% |
| 2020 Q4 | -19.09 Million EUR | 0.0% |
| 2020 Q2 | -19.9 Million EUR | 0.0% |
| 2020 FY | -38.89 Million EUR | 20.94% |
| 2019 Q2 | -22.3 Million EUR | 0.0% |
| 2019 Q4 | -26.88 Million EUR | 0.0% |
| 2019 FY | -49.19 Million EUR | -63.61% |
| 2018 Q4 | -17.09 Million EUR | 0.0% |
| 2018 FY | -30.06 Million EUR | -19.0% |
| 2018 Q2 | -12.97 Million EUR | 0.0% |
| 2017 Q2 | -11.8 Million EUR | 0.0% |
| 2017 FY | -25.26 Million EUR | -15.61% |
| 2017 Q4 | -13.45 Million EUR | 0.0% |
| 2016 FY | -21.85 Million EUR | -27.49% |
| 2016 Q2 | -10.07 Million EUR | 0.0% |
| 2016 Q4 | -11.78 Million EUR | 0.0% |
| 2015 Q4 | -9.26 Million EUR | 0.0% |
| 2015 Q2 | -7.87 Million EUR | 0.0% |
| 2015 FY | -17.14 Million EUR | -78.19% |
| 2014 Q4 | -5.41 Million EUR | 0.0% |
| 2014 FY | -9.61 Million EUR | -17.61% |
| 2014 Q2 | -4.2 Million EUR | 0.0% |
| 2013 Q3 | -2.03 Million EUR | 52.67% |
| 2013 Q2 | -4.28 Million EUR | -111.28% |
| 2013 Q1 | -2.03 Million EUR | 0.0% |
| 2013 FY | -8.17 Million EUR | -58.74% |
| 2013 Q4 | -3.89 Million EUR | -91.63% |
| 2012 Q3 | -1.29 Million EUR | 0.0% |
| 2012 Q1 | -1.29 Million EUR | 0.0% |
| 2012 Q4 | -2.03 Million EUR | -56.91% |
| 2012 FY | -5.15 Million EUR | 1.42% |
| 2012 Q2 | -1.29 Million EUR | 0.0% |
| 2011 Q3 | -1.3 Million EUR | 0.0% |
| 2011 Q2 | -1.3 Million EUR | 0.0% |
| 2011 Q1 | -1.3 Million EUR | 0.0% |
| 2011 FY | -5.22 Million EUR | 0.0% |
| 2011 Q4 | -1.29 Million EUR | 0.78% |
| 2010 Q4 | -1.3 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -684.848% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 78.976% |
| Adocia SA | -17.62 Million EUR | -51.963% |
| Aelis Farma SA | -6.46 Million EUR | -314.471% |
| Biophytis S.A. | -14.33 Million EUR | -86.835% |
| Advicenne S.A. | -6.45 Million EUR | -314.728% |
| genOway Société anonyme | 2.06 Million EUR | 1396.618% |
| IntegraGen SA | -183.77 Thousand EUR | -14472.019% |
| Medesis Pharma S.A. | -4.22 Million EUR | -533.172% |
| Neovacs S.A. | -6.9 Million EUR | -287.677% |
| NFL Biosciences SA | -4.43 Million EUR | -504.435% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -3340.983% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -753.581% |
| Sensorion SA | -22.31 Million EUR | -20.028% |
| Theranexus Société Anonyme | -7.64 Million EUR | -250.342% |
| TME Pharma N.V. | -5.62 Million EUR | -376.156% |
| Valbiotis SA | -7.16 Million EUR | -274.008% |
| TheraVet SA | -2.17 Million EUR | -1131.157% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | -31.994% |
| argenx SE | -417.15 Million EUR | 93.581% |
| BioSenic S.A. | -7.04 Million EUR | -280.384% |
| Celyad Oncology SA | -8.45 Million EUR | -216.649% |
| DBV Technologies S.A. | -85.24 Million EUR | 68.586% |
| Galapagos NV | -88.26 Million EUR | 69.66% |
| Genfit S.A. | -26.58 Million EUR | -0.749% |
| GeNeuro SA | -14.35 Million EUR | -86.518% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | -67.442% |
| Innate Pharma S.A. | -12.66 Million EUR | -111.374% |
| Inventiva S.A. | -102.7 Million EUR | 73.927% |
| MaaT Pharma SA | -19.94 Million EUR | -34.278% |
| MedinCell S.A. | -20.97 Million EUR | -27.659% |
| Onward Medical N.V. | -35.46 Million EUR | 24.487% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -488.654% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | -16.501% |
| Oxurion NV | -12.11 Million EUR | -121.131% |
| Pharming Group N.V. | -4.87 Million EUR | -448.801% |
| Poxel S.A. | -28.76 Million EUR | 6.901% |
| GenSight Biologics S.A. | -29.69 Million EUR | 9.823% |
| Transgene SA | -30.01 Million EUR | 10.772% |
| Financière de Tubize SA | -2.14 Million EUR | -1149.036% |
| UCB SA | 604 Million EUR | 104.434% |
| Valneva SE | -82.08 Million EUR | 67.377% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 7.137% |